tiprankstipranks
Trending News
More News >
Auxly Cannabis Group (OTC) (TSE:XLY)
:XLY

Auxly Cannabis Group (XLY) AI Stock Analysis

Compare
236 Followers

Top Page

TS

Auxly Cannabis Group

(OTC:XLY)

Rating:66Neutral
Price Target:
C$0.00
▼( -100.00% Downside)
Auxly Cannabis Group exhibits promising financial improvements and strong market momentum. Significant revenue growth and operational efficiencies are key strengths. However, ongoing net losses and a negative P/E ratio temper the overall outlook. The company's strong market position and strategic initiatives provide a solid foundation for future growth.

Auxly Cannabis Group (XLY) vs. iShares MSCI Canada ETF (EWC)

Auxly Cannabis Group Business Overview & Revenue Model

Company DescriptionAuxly Cannabis Group Inc. is a leading consumer packaged goods company in the cannabis products market. It operates across various sectors of the cannabis industry, including cultivation, processing, and distribution. Auxly focuses on developing, manufacturing, and distributing branded cannabis products for wellness and recreational consumers in Canada. The company's core products include a wide range of cannabis-derived goods such as dried flower, oils, capsules, and edibles.
How the Company Makes MoneyAuxly Cannabis Group generates revenue primarily through the sale of its branded cannabis products. The company's revenue model is centered around producing and distributing a diverse portfolio of cannabis products to licensed retailers and directly to consumers in jurisdictions where cannabis is legal. Key revenue streams include sales from dried cannabis flower, cannabis oil, and derivative products like edibles and beverages. Auxly further enhances its earnings through strategic partnerships and supply agreements with other cannabis producers and retailers, as well as its proprietary product development initiatives. These partnerships allow Auxly to expand its market reach and distribution capabilities, contributing significantly to its revenue.

Auxly Cannabis Group Financial Statement Overview

Summary
Auxly Cannabis Group has shown revenue growth and improvements in cash flow management but struggles with profitability, as indicated by negative net income and EBIT margins. The balance sheet shows manageable leverage, yet the negative return on equity suggests inefficiencies in generating shareholder returns.
Income Statement
35
Negative
The company has shown moderate revenue growth over the years, with a recent TTM revenue growth rate of 13.38%. However, profitability remains a concern as the company has consistently reported negative net income and EBIT margins. The gross profit margin for the TTM is 23.73%, indicating some ability to cover production costs, but significant negative EBIT (-9.16%) and EBITDA margins (-27.59%) reflect ongoing operational challenges.
Balance Sheet
40
Negative
The balance sheet reflects a moderate debt-to-equity ratio of 0.64, indicating some reliance on debt. The company has a positive equity ratio of 42.18%, suggesting a reasonable level of equity financing. However, the return on equity is negative due to persistent net losses, signaling inefficiencies in generating shareholder returns.
Cash Flow
45
Neutral
The cash flow analysis shows an improvement in operating cash flows, with a significant increase in free cash flow over the past year. The operating cash flow to net income ratio is positive at -0.29, and free cash flow to net income ratio at -0.25, reflecting improved cash management despite ongoing losses. Free cash flow growth has been substantial compared to previous years.
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
114.61M101.08M94.47M83.83M50.80M8.35M
Gross Profit
27.20M21.28M17.92M19.29M11.14M-3.71M
EBIT
-10.50M-19.00M-46.79M-42.01M-54.03M-61.05M
EBITDA
-31.61M-10.82M-93.40M-13.64M-57.18M-96.82M
Net Income Common Stockholders
-74.79M-44.51M-130.29M-45.91M-87.43M-108.62M
Balance SheetCash, Cash Equivalents and Short-Term Investments
215.06M15.75M14.78M14.89M21.50M44.44M
Total Assets
460.82M261.90M331.82M450.42M378.96M411.59M
Total Debt
94.15M159.04M193.59M190.10M124.68M99.72M
Net Debt
-117.56M143.44M178.96M175.35M103.47M55.59M
Total Liabilities
139.67M210.86M246.13M242.31M187.43M149.69M
Stockholders Equity
318.13M51.05M90.41M212.52M195.94M264.25M
Cash FlowFree Cash Flow
18.78M6.61M-11.67M-50.01M-53.86M-116.92M
Operating Cash Flow
21.38M8.21M-2.48M-49.63M-33.13M-79.12M
Investing Cash Flow
-346.00K-1.56M1.18M17.33M-14.53M-134.82M
Financing Cash Flow
-10.59M-5.68M1.18M26.40M24.74M46.36M

Auxly Cannabis Group Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.09
Price Trends
50DMA
0.08
Positive
100DMA
0.07
Positive
200DMA
0.05
Positive
Market Momentum
MACD
<0.01
Positive
RSI
50.34
Neutral
STOCH
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:XLY, the sentiment is Neutral. The current price of 0.09 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.08, and above the 200-day MA of 0.05, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.34 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:XLY.

Auxly Cannabis Group Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
67
Neutral
$29.43M17.486.18%46.04%
TSXLY
66
Neutral
C$118.17M5.3618.60%26.78%
TSOGI
64
Neutral
$250.27M17.964.76%26.93%
TSDB
63
Neutral
$40.38M2.9820.78%-15.44%
TSHLS
60
Neutral
C$147.84M-23.05%-3.73%32.70%
54
Neutral
$31.14M-16.22%16.24%46.47%
53
Neutral
$5.14B3.03-43.89%2.83%16.75%-0.06%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:XLY
Auxly Cannabis Group
0.09
0.04
88.89%
TSE:LABS
MediPharm Labs
0.08
>-0.01
-6.25%
TSE:OGI
OrganiGram Holdings
1.87
-0.61
-24.60%
TSE:DB
Decibel Cannabis Company
0.07
-0.02
-22.22%
TSE:EPIC
1CM Inc
0.25
-0.66
-72.53%
TSE:HLS
HLS Therapeutics Inc
4.68
0.84
21.87%

Auxly Cannabis Group Corporate Events

Business Operations and StrategyFinancial Disclosures
Auxly Cannabis Group Reports Strong Q1 2025 Results with Significant Revenue Growth
Positive
May 15, 2025

Auxly Cannabis Group Inc. reported a strong financial performance for the first quarter of 2025, with a 29% increase in net revenues to $32.7 million and a 232% rise in adjusted EBITDA. The company maintained its position as a top player in the Canadian cannabis market, with its Back Forty brand achieving the number one spot in Canada. Auxly’s strategic focus on innovation and operational efficiency has resulted in significant growth, reinforcing its market leadership and setting a solid foundation for future expansion.

The most recent analyst rating on (IMAX) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on IMAX stock, see the IMAX Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
Auxly Cannabis Group Achieves Record Sales and Profitability in 2024
Positive
Mar 20, 2025

Auxly Cannabis Group Inc. reported record sales and profitability for the fourth quarter and full year of 2024, with significant increases in net revenue and gross margins. The company reduced its total debt by 56% and achieved a notable market position with its Back Forty brand emerging as the top cannabis brand in Canada. These achievements underscore Auxly’s strong industry positioning and commitment to sustainable growth and value creation for stakeholders.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.